ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurobiology of Opioid Dependence: 2 - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000193
Recruitment Status : Withdrawn
First Posted : September 21, 1999
Last Update Posted : August 7, 2015
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

September 20, 1999
September 21, 1999
August 7, 2015
January 1993
January 1998   (Final data collection date for primary outcome measure)
  • Behavioral, subjective, measures of naloxone-preci
  • Phsyiological, neuroendocrine measures of naloxone
Same as current
Complete list of historical versions of study NCT00000193 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neurobiology of Opioid Dependence: 2 - 2
Neurobiology of Opioid Dependence: 2
The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
Not Provided
Interventional
Phase 2
Masking: Double
Primary Purpose: Treatment
Opioid-Related Disorders
Drug: Gamma hydroxybutyric
Not Provided
Rosen MI, Pearsall HR, Woods SW, Kosten TR. The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal. Neuropsychopharmacology. 1996 Mar;14(3):187-93.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Same as current
January 1998
January 1998   (Final data collection date for primary outcome measure)
Please contact site for information.
Sexes Eligible for Study: Male
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000193
NIDA-00191-2
K20DA000191 ( U.S. NIH Grant/Contract )
K20-00191-2
Not Provided
Not Provided
Not Provided
Yale University
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System
Yale University
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP